CASC2 is well studied in different cancers in which it acts as a tumor-suppressive lncRNA through regulating the expression of oncogenic microRNAs such as miR‐18a, miR‐21 and miR‐181a and affecting oncogenic pathways such as Wnt/β‐catenin, Ras-Raf-MEK-ERK and JNK signaling pathways 24-29, 43. The gene discussed is MAP2K7; the disease is neoplasm.